S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
Singapore‚Äôs S*BIO Pte Ltd announced it has dosed the first 10 patients in a Phase 2 clinical trial in the U.S. and Canada
Story content courtesy of S*BIO Pte Ltd, Singapore
The multi-center, open-label, study is designed to primarily evaluate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies in five sites including M.D. Anderson, Rochester University, Cornell University, University of Nebraska, and British Columbia Cancer Center. Secondary objectives include duration of response and progression-free survival.
‚ÄúThe development of SB1518 in a second indication is a significant milestone in the clinical advancement of our lead JAK2 inhibitor,‚ÄĚ said Dr. Jan-Anders Karlsson, CEO of S*BIO. ‚ÄúThe initiation of this Phase 2 trial demonstrates our commitment in advancing this best-in-class compound and addressing the unmet medical need for an effective treatment of lymphoma.‚ÄĚ
S*BIO investors include Bio*One Capital a subsidiary of EDBI (EDB Investments), Aravis Ventures, Mitsui Ventures, and Novartis Bioventures.